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Diabetic nephropathy is a growing health concern with
characteristic sterile inflammation. As the underlying
mechanisms of this inflammation remain poorly defined,
specific therapies targeting sterile inflammation in diabetic
nephropathy are lacking. Intriguingly, an association of
diabetic nephropathy with inflammasome activation has
recently been shown, but the pathophysiological relevance
of this finding remains unknown. Within glomeruli,
inflammasome activation was detected in endothelial cells
and podocytes in diabetic humans and mice and in
glucose-stressed glomerular endothelial cells and podocytes
in vitro. Abolishing Nlrp3 or caspase-1 expression in bone
marrow–derived cells fails to protect mice against diabetic
nephropathy. Conversely, Nlrp3-deficient mice are protected
against diabetic nephropathy despite transplantation of
wild-type bone marrow. Pharmacological IL-1R antagonism
prevented or even reversed diabetic nephropathy in mice.
Mitochondrial reactive oxygen species (ROS) activate the
Nlrp3 inflammasome in glucose or advanced glycation
end product stressed podocytes. Inhibition of mitochondrial
ROS prevents glomerular inflammasome activation and
nephropathy in diabetic mice. Thus, mitochondrial ROS
and Nlrp3-inflammasome activation in non-myeloid-derived
cells aggravate diabetic nephropathy. Targeting the
inflammasome may be a potential therapeutic approach
to diabetic nephropathy.
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Diabetic nephropathy is the leading cause of end-stage renal
disease in adults, putting an enormous burden on affected
individuals and health-care systems. Current therapies are
insufficient, necessitating the search for new therapeutic
strategies in diabetic nephropathy. Inflammatory processes
have been identified as potential modulators of diabetic
nephropathy. Accumulation of macrophages or T cells has
been demonstrated in humans with and in rodent models
of diabetic nephropathy.1,2 The extent of inflammatory cell
accumulation in the kidney is associated with the decline of
renal function, suggesting a causative link.1–4 Indeed, inhibi-
tion of inflammatory cell recruitment into the kidney has
been shown to be protective in experimental diabetic nephro-
pathy.5,6 Local generation of pro-inflammatory cytokines,
such as interleukin 1b (IL-1b), contributes to inflammatory
cell recruitment.3,7 Cytokines are thought to be released from
activated immune cells.3,7 However, renal cells, such as podo-
cytes, endothelial cells, or mesangial cells, can likewise secrete
pro-inflammatory cytokines and may thus aggravate diabetic
nephropathy.8–11 However, whether non-myeloid-derived
glomerular resident cells promote diabetic nephropathy by
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secreting cytokines and how cytokine secretion from these
cells may be controlled remain unknown.
The release of the pro-inflammatory cytokines IL-1b and
IL-18 is controlled by the inflammasome. Various danger
signals, including mitochondrial reactive oxygen species
(ROS), activate the Nlrp3 (nucleotide-binding domain
and leucine-rich repeat pyrin 3 domain) inflammasome.12,13
Upon detecting cellular stress, Nlrp3 recruits and assembles
with ASC (apoptosis-associated speck-like protein containing
a caspase recruitment domain) and caspase-1, resulting in
caspase-1 activation, maturation of IL-1b and IL-18, and
promotion of inflammatory cell recruitment.14 Although
initially thought to be restricted to immune cells it has been
recently shown that the inflammasome can be functional in
nonimmune cells, including podocytes.11,13,15 In addition,
inflammasome activation has lately been demonstrated in
diabetic nephropathy,16 but the pathophysiological relevance
and the mechanism of inflammasome activation in diabetic
nephropathy remain elusive. Likewise, the potential involve-
ment of glomerular resident cells, such as podocytes or
endothelial cells, for inflammasome activation in diabetic
nephropathy remains unknown. To address these questions
we evaluated the role of inflammasome activation in glo-
merular cells in the current study. Answering these questions
may be of therapeutic relevance, as the inflammasome is
amendable to therapeutic interventions.17
RESULTS
The onset of diabetic nephropathy is associated with renal
inflammasome activation
To evaluate the relevance of the inflammasome in diabetic
nephropathy we analyzed diabetic mice of various ages.
Levels of (cleaved) IL-1b and IL-18 were low in plasma
(Figure 1a) and hardly detectable in renal cortex extracts
(Figure 1b and c) of 4-week-old db/db mice, but significantly
increased in 8- and 12-week-old db/db mice. In parallel,
Nlrp3 and cleaved caspase-1 levels increased, while nephrin
expression declined in renal cortex extracts of db/db mice
with age (Figure 1b and c). Thus, inflammasome activation
occurs at an early stage of nephropathy in db/db mice.18
Albuminuria and glomerular extracellular matrix accumula-
tion (FMA, fractional mesangial area) were significantly
increased in 12, but not in 8-week-old db/db mice (Figure 1d
and e and Supplementary Figure S1a online), suggesting that
inflammasome activation precedes and may hence be
mechanistically linked with diabetic nephropathy. Changes
suggestive of nephropathy or inflammasome activation were
not apparent in nondiabetic db/m control mice (Figure 1a
and b and Supplementary Figure S1d–f online).
The renal inflammasome activation observed in db/db
mice could reflect insulin resistance and obesity19,20 and may
thus be independent of renal pathology. To address this
possibility we analyzed mice with persistent hyperglycemia
in the absence of obesity or insulin resistance (streptozotocin
(STZ) model). In these mice albuminuria and loss of nephrin
expression were likewise associated with an early increase of
Nlrp3 and cleaved IL-1b levels in the renal cortex (Figure 2
and Supplementary Figure S2 online), whereas inflamma-
some activation was not observed in nondiabetic control
mice (Figure 2a and Supplementary Figure S2d online).
Hence, renal inflammasome activation is independent of
obesity and insulin resistance.
Next, we analyzed markers of inflammasome activation in
type 2 diabetic patients in a pilot study. In albuminuric diabetic
patients, serum IL-1b levels were significantly increased
compared with diabetic patients without albuminuria or
nondiabetic controls (Figure 3a) and the degree of albumi-
nuria correlated with serum IL-1b (Figure 3b). This correla-
tion remained stable after correcting for age, sex, and disease
duration. Furthermore, Nlrp3 expression was on average
increased in glomeruli of albuminuric diabetic patients
Nlrp3
IL-1β
IL-18
IL-18
Nephrin
500
IL-18 (db/m) 105035
90030
400
*
75025
60020
300
450
200 *30010
15
NS
*
100
1505
*
NS
00
12W
*0
Pl
as
m
a 
IL
-1
β (
pg
/m
l)
Pl
as
m
a 
IL
-1
8 
(pg
/m
l)
R
el
at
iv
e 
ch
an
ge
 (%
)
4W 8W
4W 8W 12W(6)
db/db db/db
(6) (7)
FMA
4W 8W
Alb/creaNlrp3
25800
IL-18
20600Pro IL-1β
15*
*
cl IL-1β
10
400
Pro-Casp1
5200
FM
A 
(%
)
Al
b/
cr
ea
 (μ
g/
m
g)
Nephrin 00
β-Actin 8W 12W4W
12
 W
ee
ks
8 
W
ee
ks
4 
W
ee
ks12W
*
/
* * *
/ /
* * *
/ /
* *
/
cl Casp1
cl IL-1β cl IL-1β (db/m)
cl Casp1
Figure 1 | Inflammasome activation is associated with the onset
of diabetic nephropathy in db/db mice. IL-1b and IL-18 plasma
levels (a) and tissue levels of Nlrp3 (nucleotide-binding domain and
leucine-rich repeat pyrin 3 domain) and cleaved IL-1b (cl IL-1b) in
renal cortex extracts (b, c) are increased in db/db mice at 8 weeks of
age (compared with 4 weeks of age) and are further increased at age
12 weeks. Tissue levels of cleaved caspase-1 (cl Casp1) and IL-18
increase between age 4 and 8 weeks and then remain elevated
(b, c). Nephrin expression is reduced at 8 and decreases further
at 12 weeks of age (b, c). These changes are associated with a
significant increase in albuminuria (Alb) and the fractional mesangial
area (FMA) in 12- but not in 8-week-old db/db mice (d, e). Markers of
inflammasome activation (plasma IL-18, a; cleaved IL-1b, b) remain
normal in nondiabetic db/m control mice. Mean value±s.e.m.
Number of mice (a–e) in each group is shown in parentheses in
a; representative immunoblots in (c) and representative periodic
acid–Schiff–stained glomeruli in e, scale bar¼ 20 mm; *Po0.05.
FMA, fractional mesangial area; IL, interleukin; NS, not significant.
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compared to diabetic patients without albuminuria or non-
diabetic controls (Figure 3c and d).
Inflammasome inhibition ameliorates diabetic nephropathy
in mice
To explore the functional relevance of inflammasome activa-
tion in diabetic nephropathy we induced persistent hyper-
glycemia in uninephrectomized Nlrp3 / or caspase-1 /
mice using STZ. Nlrp3 or caspase-1 deficiency ameliorated
albuminuria and the FMA without affecting the body weight
or blood glucose levels (Figure 4 and Supplementary Figure
S3 online), establishing a functional role of inflammasome
activation in diabetic nephropathy.
Pathological sequelae of inflammasome activation are fre-
quently amendable to therapeutic approaches.17 Application
of the IL-1 receptor antagonist anakinra in hyperglycemic
mice with insulin resistance (db/db mice) or insulinopenia
(STZ model) reduced albuminuria and FMA (Figure 5a and b).
Treatment with anakinra (for 12 weeks) reduced the body
weight and blood glucose levels in db/db mice, but not in
insulinopenic mice (STZ model, Supplementary Figure S4a–c
online), illustrating that anakinra can ameliorate diabetic
nephropathy independent of its metabolic effects. Of note, in
12-week-old db/db mice with established nephropathy18 (and
current data) the intervention with anakinra for 8 weeks
normalized albuminuria and FMA (Figure 5c). Thus, inhibi-
tion of IL-1 receptor signaling can not only prevent, but also
reverse, diabetic nephropathy in mice.
Hyperglycemia triggers inflammasome activation in
glomerular cells
Whether inflammasome activation occurs in glomerular cells
in diabetic nephropathy and the potential implications of this
remained unknown hitherto. Using confocal microscopy we
observed partial colocalization of Nlrp3 or cleaved caspase-1
with podocytes and glomerular endothelial cells in histological
sections of diabetic humans or mice, respectively (Figure 6a
and b, Supplementary Figure S5a online). In 12-week-old
db/db mice cleaved caspase-1 localized predominately to
glomeruli (Supplementary Figure S5b online).
In vitro glucose, but not mannitol, induced Nlrp3 expres-
sion cell-autonomously and cleaved IL-1b in glomerular
endothelial cells and podocytes (Figure 6c). Furthermore,
cleaved IL-1b was readily observed in primary podocytes
isolated from C57BL/6 wild-type mice and was induced
following glucose, but not mannitol, treatment (Figure 6d).
Of note, only pro-IL-1b, but not cleaved IL-1b, could be
detected in primary podocytes isolated from caspase-1 /
mice (Figure 6d), consistent with cell-autonomous matura-
tion of IL-1b in podocytes.
Inflammasome deficiency in bone marrow–derived cells fails
to ameliorate early stages of diabetic nephropathy
To address the pathogenic relevance of inflammasome
activation in myeloid vs. non-myeloid-derived cells, we next
conducted bone marrow transplantation experiments. First,
Nlrp3 / , caspase-1 / , or wild-type (control) bone
marrow was transplanted into lethally irradiated db/db mice
(age 8 weeks, Figure 7a). This had no impact on body weight,
blood glucose levels (Supplementary Figure S6 online), or the
glomerular frequency of CD11cþ cells (Figure 7b). Of note,
in db/db mice transplanted with Nlrp3 / bone marrow no
cleaved caspase-1 could be detected in glomerular CD11cþ
cells (Figure 7c). In comparison to control db/db mice
albuminuria and FMA increased to the same extend in db/db
mice transplanted with Nlrp3 / or caspase-1 / bone
marrow after 12 weeks (Figure 7d and e). Thus, Nlrp3- or
caspase1-deficiency in bone marrow–derived cells does not
ameliorate diabetic nephropathy in mice.
Next, we conducted the reverse experiment transplanting
wild-type bone marrow into Nlrp3 / mice to evaluate the
role of the Nlrp3 inflammasome in glomerular resident cells
(Figure 7f). As Nlrp3 / mice are not readily available on a
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Figure 2 | Inflammasome activation is associated with the onset
of diabetic nephropathy in streptozotocin (STZ)-treated C57BL/6
mice. Tissue levels of Nlrp3 (nucleotide-binding domain and leucine-
rich repeat pyrin 3 domain) and cleaved interleukin-1b (cl IL-1b)
increase, whereas expression of nephrin declines in renal cortex
extracts of diabetic C57BL/6 mice (STZ model; a, b). Inflammasome
activation is paralleled by an increase in albuminuria and fractional
mesangial area (FMA, c, d; overviews for d in Supplementary Figure
S2a online). Cleaved IL-1b remains normal in nondiabetic C57BL/6
control mice (no DM, a). Mean value±s.e.m. Number of mice (a–d)
in each group is shown in parentheses in a; representative
immunoblots in b and periodic acid Schiff-stained glomeruli in d,
scale bar¼ 20mm; *Po0.05. DM, diabetic mice; NS, not significant.
76 Kidney International (2015) 87, 74–84
bas i c resea rch K Shahzad et al.: Inflammasome aggravates diabetic nephropathy
db/db background we used the STZ model. Following trans-
plantation of wild-type bone marrow into Nlrp3 / mice,
body weight, blood glucose levels, and the presence of
CD11cþ cells in glomeruli (Figure 7g, Supplementary Figure
S6 online) were not altered. Of note, albuminuria and FMA
remained normal in diabetic and nondiabetic Nlrp3 /
mice despite reconstitution with wild-type bone marrow
(Figure 7h and i). These data suggest that inflammasome
activation primarily in renal resident cells contributes to
diabetic nephropathy.
Inflammasome activation by mitochondrial ROS in diabetic
mice
Mitochondrial ROS promote diabetic nephropathy21,22 and
can trigger Nlrp3-inflammasome activation.13,23 To evaluate
whether mitochondrial ROS are mechanistically linked with
glomerular Nlrp3-dependent inflammasome activation we
used the mitochondria-targeted antioxidant MitoTempo,
a superoxide dismutase mimetic that accumulates in mito-
chondria.24 MitoTempo reduced mitochondrial ROS
(Supplementary Figure S7a online) and in parallel Nlrp3
levels and IL-1b activation in glucose-stressed podocytes
(Figure 8a and b).
Enhanced glycolytic flux is sufficient to increase mito-
chondrial ROS, but glucose-modified proteins such as AGEs
(advanced glycation endproducts) may likewise induce mito-
chondrial ROS generation through a RAGE (receptor for
AGEs)-dependent mechanism.25 Indeed, AGE-BSA induced
Nlrp3 expression and IL-1b cleavage in podocytes, an effect
that was prevented by RAGE inhibition (Figure 8a and b).
Thus, glucose and glucose-induced metabolites may synergis-
tically contribute to ROS-dependent inflammasome activa-
tion, in particular in the in vivo situation. Of note, MitoTempo
failed to reduce levels of cleaved IL-1b in glucose-stressed
human podocytes transfected with the constitutive active
human Nlrp3 mutant Q705K,26 indicating ROS triggered
Nlrp3-dependent IL-1b maturation in podocytes (Figure 8c).
To evaluate the role of mitochondrial ROS for inflamma-
some activation in vivo we next treated db/db and
uninephrectomized diabetic C57BL/6 mice (STZ model,
STZ mice) with MitoTempo. MitoTempo treatment had no
effect on body weight or blood glucose levels (Supplementary
Figure S7b online). In db/db mice, MitoTempo treatment
markedly reduced levels of Nlrp3, cleaved IL-1b, albuminur-
ia, and FMA in comparison with control db/db mice
(Figure 8d–f). Likewise, indices of diabetic nephropathy
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and inflammasome activation were reduced in MitoTempo-
treated STZ mice when compared with phosphate-buffered
saline-treated diabetic controls (Figure 9a–d).
Genetic ablation of p66Shc reduces mitochondrial ROS
and protects mice from diabetic nephropathy.21 Again, persi-
stent hyperglycemia failed to induce Nlrp3 expression and
IL-1b cleavage in p66Shc deficient diabetic mice (Figure 10a–c),
supporting a critical role of mitochondrial ROS for inflam-
masome activation in diabetic nephropathy.
DISCUSSION
Diabetic nephropathy is considered an inflammatory disease,
and several reports recently demonstrated inflammasome
activation in association with diabetic nephropathy. In the
current study we establish that inflammasome activation is
causatively linked with diabetic nephropathy. IL-1 receptor
antagonism or inhibition of mitochondrial ROS, an estab-
lished activator of the Nlrp3 inflammasome, ameliorates
diabetic nephropathy in mice, suggesting that interventions
targeting this mechanism of sterile inflammation may be a
feasible therapeutic approach in diabetic nephropathy.
Although originally thought to be specific for the innate
immune system, inflammasome activation and signaling has
recently been described in cells not belonging to the immune
system.13,15,27 Previous to the currently observed hyperglycemia-
associated inflammasome activation in podocytes, similar
observations have been made in mice with hyperhomocy-
steinanemia or diet-induced obesity.8,11,28 In addition to
these reports we observed inflammasome activation in glo-
merular endothelial cells, suggesting that inflammasome
activation in various kidney cells may contribute to diabetic
nephropathy. Indeed, kidney-restricted silencing of ASC,
an adaptor protein required for the inflammasome
complex, attenuated proteinuria, albuminuria, and glome-
rular sclerosis.8,11,28 This approach, however, targets all cells
within the kidney, including inflammatory cells. Thus,
although demonstrating a role of inflammasome activation
in glomerular disease, the question as to whether inflam-
masome activation in resident glomerular cells, such as
podocytes or endothelial cells, contributes to glomerular
sclerosis remained unresolved in these studies.
To address this question we conducted bone marrow–
transplantation experiments, which demonstrated that
inflammasome activation in renal resident cells, but not in
bone marrow–derived cells, is sufficient to trigger diabetic
nephropathy in mice. We acknowledge that the chosen
method, bone marrow transplantation, has limitations and
that cell-specific inactivation of inflammasome regulators
such as Nlrp3 or caspase-1 would be preferred. Cell-specific
deletion would likewise enable a researcher to specifically
address the role of inflammasome activation in glomerular
and tubular cells. However, mice with conditional inactiva-
tion of Nlrp3 or caspase-1 are currently not readily available.
In addition, inflammasome activation occurred at least in
podocytes and endothelial cells. Hence, genetic inflamma-
some inactivation in multiple renal cell types will be required
to address the functional role of inflammasome activation
in resident glomerular cells vs. bone marrow–derived cells.
Considering these obstacles, we believe that the chosen
method constitutes a reasonable approach. In view of the
current data, more sophisticated experimental approaches to
clarify the role of inflammasome activation in renal resident
cells are now justified and required.
Following transplantation of Nlrp3-deficient bone marrow
we failed to detect CD11cþ cells with signs of inflamma-
some activation in renal glomeruli, indicating efficient
replacement of renal dendritic cells. This is consistent with
the replacement of innate immune cells in tissues such as
skin, lung, or liver following bone marrow transplanta-
tion.29–32 While persistence of some Nlrp3 or caspase-1-
expressing innate immune cells in the kidney despite bone
marrow transplantation cannot be excluded, the current data
argue against a role of inflammasome activation in cells
actively recruited from the bone marrow into the kidney
during the disease course. This, however, does not exclude a
pathogenetic function of bone marrow–derived cells in the
course of diabetic nephropathy. Bone marrow–derived cells
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may aggravate the disease progression independent of the
inflammasome, as previously proposed.6,7,33,34 In addition,
we cannot exclude that inflammasome activation in bone
marrow–derived cells contributes to the later disease stages or
interstitial tissue damage. On the basis of available data it
appears possible that inflammasome activation in renal
resident cells including glomerular cells triggers recruitment
of bone marrow–derived cells, which then aggravate the
disease progression. This possibility has to be experimentally
evaluated.
Inflammasome inhibition may be superior to blocking
inflammatory cell recruitment1,5 as IL-1b and IL-18 impair
podocyte and endothelial function independent of inflam-
matory cell recruitment.35 Whether modulation of noncano-
nical functions of Nlrp3, such as the Nlrp3-dependent
modulation of Smad2/3 phosphorylation by transforming
growth factor-b in tubular cells,36 will constitute an
additional benefit of inflammasome inhibition remains to
be evaluated.
The identification of mitochondrial ROS as the Nlrp3
activator in diabetic glomeruli provides a mechanistic link
between ROS and sterile inflammation in diabetic nephro-
pathy.12,21,22,37 ROS-dependent activation of the Nlrp3
inflammasome has been recently described in monocytes
and macrophages from diabetic patients,38 indicating that
this pathway is also functional in non-renal cells. Mito-
chondrial ROS have been proposed as a common pathway
mediating Nlrp3 activation.12,37 Mitochondrial ROS
dissociate TxNIP from thioredoxin, and free TxNIP can
bind to and activate Nlrp3.12,13,39 In addition, accumulation
of dysfunctional, ROS-generating mitochondria is sufficient
to activate the Nlrp3 inflammasome.12,13 Although we used
two independent approaches to evaluate the relevance
of mitochondrial ROS (MitoTempo- and p66Shc-deficient
mice), tools to specifically inhibit ROS in glomerular cells
were not available to us. Hence, stringent evidence pinpoint-
ing a causative role of glomerular-derived mitochondrial
ROS is still pending.
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Mitochondrial ROS do not only mediate harmful effects
but are also required for maintaining cellular homeostasis.40
This dual function may limit the therapeutic efficacy of mito-
chondrial-targeted ROS inhibition. Rather, cell-damaging
pathways initiated by ROS, but amendable to therapeutic
interventions, ought to be identified. Mitochondrial ROS
activate the inflammasome, and inhibition of inflammasome
signaling using anakinra provided nephroprotection and
even reversed diabetic nephropathy in the current study,
whereas inhibition of mitochondrial ROS using MitoTempo
was only partially protective. Thus, inflammasome inhibi-
tion, which is already clinically established,17 constitutes a
feasible therapeutic target.
Inflammasome inhibition in diabetic patients may provide
additional benefits due to its metabolic effects.19,20,41 Indeed,
we observed a reduction in body weight and blood glucose
levels in db/db mice. Yet, anakinra conveyed nephropection
not only in db/db mice, but also in mice with STZ-induced
insulinopenia and hyperglycemia (reflecting type 1 diabetes).
Hence, nephroprotection by inflammasome inhibition is at
least partially independent of these metabolic effects. The
efficacy, feasibility, and safety of inflammasome inhibition in
patients with diabetic nephropathy, potentially using small
molecule inhibitors,42 remains to be evaluated.
The current findings extend recent studies imputing
an immune modulatory function to podocytes.43–46 Thus,
besides inflammasome activation8,11 (and current study)
podocytes are competent to signal via TLR,44,45 to modulate
complement,43,46,47 and to activate naive T cells following
antigen presentation.45 The ability of podocytes to sense
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danger signals and to initiate an immune response may
render the glomerular filtration barrier not only sensitive to
inflammatory disease, but in addition endow the kidney,
which continuously controls a large portion of the body’s
blood, with an immune-surveillance function, reminiscent of
the dual function of teleost’s kidneys.48 These immunological
functions may be pathologically relevant not only in infec-
tious or autoimmune diseases.49 Rather, the current and
previous studies50 suggest that sterile inflammation in the
kidney may be of pathogenic relevance in the context of
metabolic diseases. This may lay ground for novel therapeutic
approaches to nephropathies associated with metabolic
diseases.
MATERIALS AND METHODS
See online Supplementary materials for additional information.
Mice
Caspase1 / , db/db (Lepr db/db), and nondiabetic db/m control
mice (C57BL/6J background) were obtained from Jackson
Laboratories, Bar Harbor, ME. p66shc / and Nlrp3 / mice
have been previously described.21,51,52 In the current study we used
littermates that have been backcrossed for at least 10 generations on
a C57BL/6 or C57BL/6J background. All animal experiments were
conducted following standards and procedures approved by the
local Animal Care and Use Committee (Landesverwaltungsamt
Halle, Germany).
Diabetic nephropathy models
Two different STZ-dependent models of diabetic nephropathy were
used in the current study. A long-term model (24 weeks) following a
previously published protocol21,46,53,54 was used in genetically modi-
fied p66Shc / mice and their controls. In these mice, persistent
hyperglycemia was induced by intraperitoneal administration
of 60mg/kg STZ freshly dissolved in 0.05mol/l sterile sodium
citrate at pH 4.5 for 5 consecutive days in 8-week-old mice, as
described.21,46,53,54
In addition we used the unilateral nephrectomy model of diabetic
nephropathy.21,55 This short-term model is particularly useful to test
therapeutic interventions. Briefly, 8-week-old mice were anesthetized
with pentobarbital (1mg/kg body weight, intraperitoneally). A
dorso-lumbar incision (approximately 1 cm) was made and the
ureter, the renal artery, and renal vein were ligated and subsequently
severed. The kidney was removed and the incision was sutured. Two
weeks after surgery, diabetes was induced by injections of STZ
(intraperitoneally, 40mg/kg body weight, freshly dissolved in
0.05mol/l sterile sodium citrate, pH 4.5) for 5 consecutive days.
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Age-matched control mice received 100ml phosphate-buffered saline
intraperitoneally for 5 consecutive days.
In both models mice were considered diabetic if blood glucose
levels were above 300mg/dl 16 d after the last STZ injection.21,53,54
Blood glucose levels were determined from blood samples taken
from the tail vein by using ACCU-CHEK glucose strips. In the first
3 weeks after the onset of diabetes, blood glucose values were
measured three times per week, and thereafter once per week.21,53,54
Mice with blood glucose levels above 500mg/dl received 1–2U of
insulin (Lantus) to avoid excessive and potentially lethal hypergly-
cemia.21,53,54 Blood and tissue samples were obtained after 24 weeks
(long-term model) or 8 weeks (short-term model) of persistent
hyperglycemia in diabetic mice. Age-matched littermates served as
controls.
In vivo intervention studies
A subset of mice was treated with the IL-1R antagonist (Anakinra,
10mg/kg, intraperitoneally)56 or the mitochondria-targeted antioxidant
MitoTempo (700 mg/kg body weight per day; subcutaneous).57
Interventions with Anakinra or MitoTempo were initiated in
8-week-old db/db mice to determine its preventive effect. In
uninephrectomized, STZ-treated mice, treatment with Anakinra or
MitoTempo was initiated 2 weeks after establishment of stable
hyperglycemia and continued for 8 weeks. Treatment with anakinra
was initiated in 12-week-old db/db mice to determine its effect after
onset of diabetic nephropathy. Control mice were injected with
phosphate-buffered saline.
Analyses of human samples
Patients (N¼ 87) with type 2 diabetes, according to the American
Diabetes Association criteria,58 were recruited from the diabetes
outpatient clinic at the University Hospital Heidelberg. Micro-
albuminuria was diagnosed if at least two separate urine samples out
of three consecutive urine samples (albumin excretion rate
AERX30mg/24 h) were positive. Nondiabetic control subjects
(N¼ 33) were recruited at the outpatient clinic of the University
Hospital Heidelberg and Magdeburg. Nondiabetic controls had
either stable and minor osteoporosis or stable and well-controlled
thyroid function (e.g., after thyreoidectomy). Nondiabetic controls
were on vitamin D and calcium substitution only (osteoporosis
patients) or thyroid hormones, but no other medication. All
patients and controls were Caucasian. The study complied with the
Declaration of Helsinki; all patients entered the study according to
the guidelines of the local ethics committees after giving informed
consent (Ethic-Committee-No: 204/2004).
Statistical analysis
The data are summarized as the mean±s.e.m. (standard error of the
mean). Statistical analyses were performed with Student’s t-test and
analysis of variance. Post-hoc comparisons of analysis of variance
were corrected with the method of Tukey. For the patient data,
Pearson’s correlation coefficient (r) was determined and the two-
tailed P-value is given. The correlation was corrected for age, sex,
disease duration, and estimated glomerular filtration rate by
multiple regression analysis. StatistiXL (www.statistixl.com) and
Prism 5 (www.graphpad.com) software were used for statistical
analyses. Statistical significance was accepted at values of Po0.05.
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